Loading patent…
OwnerStefan Schreiber, Philip Rosenstiel +6inventors
InventorsStefan Schreiber, Philip Rosenstiel, Andreas Ruether, Andre Franke, John Raelson, Randall D. Little, Tim Keith, Helene Fournier
Estimating the term…
The invention provides methods for evaluating irritable bowel disease (IBD), including Crohn Disease and Ulcerative Colitis, methods for determining a patient's susceptibility to developing an IBD, and methods for determining a patient's IBD genotype. The invention includes methods, polynucleotides, polypeptides, and antibodies relating to disclosed variants of, and polymorphisms in, the nel-like 1 precursor (NELL1), as well as the 5p13.1 locus, and other genes disclosed herein to be associated with IBD. Thus, the invention provides diagnostic and/or therapeutic targets for IBD, as well as diagnostic and therapeutic agents for IBD.
A method for determining inflammatory bowel disease (IBD) genotype in a patient suspected of having an IBD, or for determining a patient's susceptibility to develop an IBD, said method comprising:
-12. (canceled)
(canceled)
-21. (canceled)
A kit for determining inflammatory bowel disease (IBD) genotype in a patient suspected of having an IBD, or for determining a patient's susceptibility to develop an IBD, said kit comprising a set of nucleic acid probes and/or primers specific designed to detect two or more SNP(s) listed in any one of Tables 1-5, wherein the set of probes and/or primers consists essentially of probes and/or primers related to evaluating said IBD genotype and probes and/or primers related to assay controls.
A NELL1 polypeptide comprising at least one amino acid substitution that is associated with IBD.
-32. (canceled)
A method for identifying an agent for treating IBD, comprising contacting a NELL1 polypeptide with a test agent, and determining a change in the level of NELL1 activity as a result of the test agent.
Dependencies are inferred from the claim text.